Biosimilars bills move on in two US states

Home/Policies & Legislation | Posted 15/03/2013 post-comment0 Post your comment

The battle over biosimilar drugs is heating up in the US, with two states moving biosimilar bills along in the substitutability of biosimilars.

US map CO+FL V13C15

In the Florida House, the Health Quality Subcommittee approved a bill on 19 February 2013 creating standards for using biosimilars.

The House Bill 365 sponsored by House Representative Matt Hudson, provides a mechanism that would allow pharmacists to substitute a biosimilar for a brand-name drug in a manner similar to one now used to dispense generic drugs. It would, however, require the pharmacist to notify the prescribing physician within five days of the substitution and require the physician and pharmacist to maintain a record of the substitution for at least four years.

Meanwhile, in the Colorado House a similar bill was passed by an overwhelming 10–1 majority.

House Bill 1121 sponsored by House Representatives Sue Schafer and Carole Murray allows for substitution of biosimilars for brand-name biological drugs if the pharmacist notifies the patient orally and in writing, notifies the prescribing physician of the switch and keeps a record of the switch for five years. Senator Irene Aguilar, Chairwoman of the Senate Health and Human Services Committee, has said, however, that the bill ‘may have a harder time making it through her chamber’. The Senator is concerned that the bill ‘will discourage pharmacists from suggesting a biosimilar substitution, thereby doing nothing to lower the cost of health care’.

These bills are just a few of several bills in statehouses across the US that are seeking to enable the first biosimilars to come onto the market in the US within two years.

The bills would only allow biosimilar substitution if cumbersome conditions were met by physicians and pharmacists. Generics makers, pharmacists and pharmacy benefit managers, on the other hand, support automatic substitution of biosimilars deemed interchangeable with their brand-name biological and have called the legislation premature, given the fact that FDA is yet to issue final guidelines for the biosimilar approval process.

FDA has also defended the substitution of interchangeable biosimilars, with FDA Commissioner Margaret Hamburg saying that attempts to undermine trust in biosimilars are ‘worrisome and represent a disservice to patients who could benefit from these lower cost treatments’ [1].

Editor’s comment
Please feel free to share your thoughts via email or in the comments section below. Is such legislation trying to limit biosimilar substitution in the US? Or will these bills really just ensure patient safety?

Related article

FDA finally issues draft biosimilar guidance

References

1.  GaBI Online - Generics and Biosimilars Initiative. US FDA defends biosimilar substitution [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Mar 15]. Available from: www.gabionline.net/Biosimilars/General/US-FDA-defends-biosimilar-substitution

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Denver Business Journal, HT Politics

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010